
Analgesics in Singapore
Description
Analgesics in Singapore
Demand for systemic analgesics continued to normalise in Singapore in 2024 following the surge in purchases seen in 2022. During the peak of the COVID-19 pandemic and its aftermath, consumers stockpiled these products to self-medicate for post-vaccination symptoms and common cold symptoms caused by later variants of the virus. With the threat of COVID-19 having largely been mitigated, the urgency to purchase systemic analgesics has decreased, leading to a stabilisation in the growth rate.
Euromonitor International's Analgesics in Singapore report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2020-2024, allowing you to identify the sectors driving growth. Forecasts to 2029 illustrate how the market is set to change.
Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Table of Contents
25 Pages
- Analgesics in Singapore
- Euromonitor International
- January 2025
- List Of Contents And Tables
- ANALGESICS IN SINGAPORE
- KEY DATA FINDINGS
- 2024 DEVELOPMENTS
- Demand for systemic analgesics continues to normalise with acetaminophen remaining the preferred choice
- Continued healthy growth for topical analgesics, driven by revival of inbound travel and growing demand for natural pain relief solutions
- GSK Consumer Healthcare maintains leadership, despite rising competition
- PROSPECTS AND OPPORTUNITIES
- Demand for systemic analgesics will remain strong, alongside normalisation of consumer lifestyles
- Evolving demographics will enable stable growth in topical analgesics/anaesthetic
- Rise of teleconsulting could hinder sales of OTC analgesics
- CATEGORY DATA
- Table 1 Sales of Analgesics by Category: Value 2019-2024
- Table 2 Sales of Analgesics by Category: % Value Growth 2019-2024
- Table 3 NBO Company Shares of Analgesics: % Value 2020-2024
- Table 4 LBN Brand Shares of Analgesics: % Value 2021-2024
- Table 5 Forecast Sales of Analgesics by Category: Value 2024-2029
- Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2024-2029
- CONSUMER HEALTH IN SINGAPORE
- EXECUTIVE SUMMARY
- Consumer health in 2024: The big picture
- 2024 key trends
- Competitive landscape
- Retailing developments
- What next for consumer health?
- MARKET INDICATORS
- Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2019-2024
- Table 8 Life Expectancy at Birth 2019-2024
- MARKET DATA
- Table 9 Sales of Consumer Health by Category: Value 2019-2024
- Table 10 Sales of Consumer Health by Category: % Value Growth 2019-2024
- Table 11 NBO Company Shares of Consumer Health: % Value 2020-2024
- Table 12 LBN Brand Shares of Consumer Health: % Value 2021-2024
- Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2019-2024
- Table 14 Distribution of Consumer Health by Format: % Value 2019-2024
- Table 15 Distribution of Consumer Health by Format and Category: % Value 2024
- Table 16 Forecast Sales of Consumer Health by Category: Value 2024-2029
- Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2024-2029
- APPENDIX
- OTC registration and classification
- Vitamins and dietary supplements registration and classification
- Self-medication/self-care and preventive medicine
- Switches
- DISCLAIMER
- DEFINITIONS
- SOURCES
- Summary 1 Research Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.